• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Promethazine by Strides Shasun approved by USFDA

biospectrumasiaJuly 04, 2017

Tag: Promethazine , USFDA

Strides Shasun has recently received an approval from the United States Food & Drug Administration (USFDA) for Promethazine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg.

According to IMS data, the US market for Promethazine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg is approximately $ 17 million.

The product will be manufactured at the company’s flagship facility at Bangalore and marketed by Strides Pharma Inc. in the US Market.

Promethazine Hydrochloride Tablet is used to prevent and treat nausea and vomiting related to certain conditions and also to treat allergy symptoms such as rash, itching, and runny nose.

Previous:TissueGene awarded $750,000 Maryland Stem Cell Grant for Invossa clinical study

Next:Amgen’s uncontrolled LDL cholesterol lowering drug available in Singapore

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Promethazine by Strides Shasun approved by USFDA | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min
PROMETHAZINE INJ.

PROMETHAZINE INJ.
Promethazine Hcl   Injection 

Promethazine Hcl   Injection 
Dioxopromethazine Hydrochloride

Dioxopromethazine Hydrochloride
Promethazine hydrochloride

Promethazine hydrochloride
Best supply of Promethazine hydrochloride

Best supply of Promethazine hydrochloride
99% up GMP DMF Promethazine 60-87-7

99% up GMP DMF Promethazine 60-87-7
Promethazine hcl58-33-3

Promethazine hcl58-33-3
Promethazine EP Impurity C HCl

Promethazine EP Impurity C HCl
Promethazine   hydrochloride Tablets 

Promethazine   hydrochloride Tablets 

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service